WO2001090148A3 - Neurotransmitter transporters - Google Patents

Neurotransmitter transporters Download PDF

Info

Publication number
WO2001090148A3
WO2001090148A3 PCT/US2001/016283 US0116283W WO0190148A3 WO 2001090148 A3 WO2001090148 A3 WO 2001090148A3 US 0116283 W US0116283 W US 0116283W WO 0190148 A3 WO0190148 A3 WO 0190148A3
Authority
WO
WIPO (PCT)
Prior art keywords
ntt
provides
neurotransmitter transporters
polynucleotides
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/016283
Other languages
French (fr)
Other versions
WO2001090148A8 (en
WO2001090148A2 (en
Inventor
Madhu S Sanjanwala
Narinder K Walia
Catherine M Tribouley
Henry Yue
Ameena R Gandhi
Li Ding
Monique G Yao
Preeti Lal
Mariah R Baughn
April Hafalia
Vicki S Elliott
Chandra Patterson
Jaya Rankumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to JP2001586959A priority Critical patent/JP2004514411A/en
Priority to EP01937593A priority patent/EP1355943A2/en
Priority to AU2001263310A priority patent/AU2001263310A1/en
Priority to CA002408141A priority patent/CA2408141A1/en
Publication of WO2001090148A2 publication Critical patent/WO2001090148A2/en
Publication of WO2001090148A8 publication Critical patent/WO2001090148A8/en
Anticipated expiration legal-status Critical
Publication of WO2001090148A3 publication Critical patent/WO2001090148A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention provides human neurotransmitter transporter (NTT) and polynucleotides which identify and encode NTT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NTT.
PCT/US2001/016283 2000-05-19 2001-05-17 Neurotransmitter transporters Ceased WO2001090148A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001586959A JP2004514411A (en) 2000-05-19 2001-05-17 Neurotransmitter transporter
EP01937593A EP1355943A2 (en) 2000-05-19 2001-05-17 Neurotransmitter transporters
AU2001263310A AU2001263310A1 (en) 2000-05-19 2001-05-17 Neurotransmitter transporters
CA002408141A CA2408141A1 (en) 2000-05-19 2001-05-17 Neurotransmitter transporters

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US20551800P 2000-05-19 2000-05-19
US60/205,518 2000-05-19
US21395600P 2000-06-22 2000-06-22
US60/213,956 2000-06-22
US21510500P 2000-06-28 2000-06-28
US60/215,105 2000-06-28
US21894700P 2000-07-14 2000-07-14
US60/218,947 2000-07-14
US22148800P 2000-07-27 2000-07-27
US60/221,488 2000-07-27

Publications (3)

Publication Number Publication Date
WO2001090148A2 WO2001090148A2 (en) 2001-11-29
WO2001090148A8 WO2001090148A8 (en) 2002-07-04
WO2001090148A3 true WO2001090148A3 (en) 2003-08-14

Family

ID=27539524

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016283 Ceased WO2001090148A2 (en) 2000-05-19 2001-05-17 Neurotransmitter transporters

Country Status (5)

Country Link
EP (1) EP1355943A2 (en)
JP (1) JP2004514411A (en)
AU (1) AU2001263310A1 (en)
CA (1) CA2408141A1 (en)
WO (1) WO2001090148A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077045A1 (en) * 1999-06-10 2000-12-21 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
GB0207533D0 (en) * 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
CN1395103A (en) * 2002-07-31 2003-02-05 中华人民共和国北京出入境检验检疫局 Piezoelectric biological chip for detecting disease cause of mad cattle disease and its preparation method
CN118141894A (en) * 2024-02-04 2024-06-07 河北医科大学 Application of DBI and hydrolysate peptide thereof in preparation of medicine for relieving peripheral nerve pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018143A1 (en) * 1992-03-04 1993-09-16 Synaptic Pharmaceutical Corporation Dna encoding taurine and gaba transporters and uses thereof
WO2000077045A1 (en) * 1999-06-10 2000-12-21 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
WO2001077321A2 (en) * 2000-04-07 2001-10-18 Merck Patent Gmbh Identification of a human gaba transporter

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018143A1 (en) * 1992-03-04 1993-09-16 Synaptic Pharmaceutical Corporation Dna encoding taurine and gaba transporters and uses thereof
WO2000077045A1 (en) * 1999-06-10 2000-12-21 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
WO2001077321A2 (en) * 2000-04-07 2001-10-18 Merck Patent Gmbh Identification of a human gaba transporter

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARNWELL L F S ET AL: "Cloning and sequencing of a cDNA encoding a novel member of the human brain GABA/noradrenaline neurotransmitter transporter family", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 159, no. 2, 4 July 1995 (1995-07-04), pages 287 - 288, XP004042226, ISSN: 0378-1119 *
BORDEN L A ET AL: "MOLECULAR HETEROGENEITY OF THE GAMMA-AMINOBUTYRIC ACID (GABA) TRANSPORT SYSTEM", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 267, no. 29, 15 October 1992 (1992-10-15), pages 21098 - 21104, XP002916398, ISSN: 0021-9258 *
RASOLA A ET AL: "MOLECULAR CLONING AND FUNCTIONAL CHARACTERIZATION OF A GABA/BETAINETRANSPORTER FROM HUMAN KIDNEY", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 373, 1995, pages 229 - 233, XP002932543, ISSN: 0014-5793 *
SCHULDINER S ET AL: "VESICULAR NEUROTRANSMITTER TRANSPORTERS: FROM BACTERIA TO HUMANS", PHYSIOLOGICAL REVIEWS, AMERICAN PHYSIOLOGICAL SOCIETY, US, vol. 75, no. 2, 1 April 1995 (1995-04-01), pages 369 - 392, XP000199557, ISSN: 0031-9333 *

Also Published As

Publication number Publication date
JP2004514411A (en) 2004-05-20
WO2001090148A8 (en) 2002-07-04
AU2001263310A1 (en) 2001-12-03
CA2408141A1 (en) 2001-11-29
EP1355943A2 (en) 2003-10-29
WO2001090148A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
WO2002046383A3 (en) Protein modification and maintenance molecules
WO2001098351A3 (en) G-protein coupled receptors
WO2002004520A3 (en) Transporters and ion channels
WO2001046258A3 (en) Transporters and ion channels
WO2002012340A3 (en) Transporters and ion channels
WO2001057085A3 (en) G-protein coupled receptors
WO2001087937A3 (en) G-protein coupled receptors
WO2002040541A3 (en) Transporters and ion channels
WO2001098354A3 (en) Human receptors
WO2001098323A8 (en) G-protein coupled receptors
WO2002022684A3 (en) Transporters and ion channels
WO2002002603A3 (en) Protein modification and maintenance molecules
WO2001092304A3 (en) Transporters and ion channels
WO2002097060A3 (en) Carbohydrate-associated proteins
WO2001072836A3 (en) G-protein coupled receptors
WO2002034783A3 (en) Transmembrane proteins
WO2002026950A3 (en) Transferases
WO2001062923A3 (en) Transporters and ion channels
WO2003031568A8 (en) Intracellular signaling molecules
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2001077174A3 (en) Human transporters and ion channels
WO2001090359A3 (en) G-protein coupled receptors
WO2002026825A3 (en) G-protein coupled receptors
WO2000065054A3 (en) Human membrane-associated proteins
WO2001066742A3 (en) G-protein coupled receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
WWE Wipo information: entry into national phase

Ref document number: 2408141

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001937593

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001937593

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001937593

Country of ref document: EP